-
公开(公告)号:CA2219460A1
公开(公告)日:1996-12-19
申请号:CA2219460
申请日:1996-06-07
Applicant: INDIANA UNIVERSITY FOUNDATION
Inventor: ROESKE ROGER W
Abstract: Novel LHRH antagonist peptides, pharmaceutical compositions thereof, and methods of use thereof, are disclosed. The LHRH antagonist comprise a peptide compound, wherein a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH comprises a hydrophilic N-acyl moiety, a dipolar moiety, a sulfonium moiety, a receptor-modifying moiety or a small polar moiety.
-
公开(公告)号:AU3130100A
公开(公告)日:2000-07-06
申请号:AU3130100
申请日:2000-05-03
Applicant: INDIANA UNIVERSITY FOUNDATION
Inventor: ROESKE ROGER W
-
公开(公告)号:CA2219460C
公开(公告)日:2009-04-14
申请号:CA2219460
申请日:1996-06-07
Applicant: INDIANA UNIVERSITY FOUNDATION
Inventor: ROESKE ROGER W
Abstract: Novel LHRH antagonist peptides, pharmaceutical compositions thereof, and methods of use thereof, are disclosed. The LHRH antagonist comprise a peptide compound, wherein a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH comprises a hydrophilic N-acyl moiety, a dipolar moiety, a sulfonium moiety, a receptor-modifying moiety or a small polar moiety.
-
公开(公告)号:AU715399B2
公开(公告)日:2000-02-03
申请号:AU6168096
申请日:1996-06-07
Applicant: INDIANA UNIVERSITY FOUNDATION
Inventor: ROESKE ROGER W
Abstract: Novel LHRH antagonist peptides, pharmaceutical compositions thereof, and methods of use thereof, are disclosed. The LHRH antagonist comprise a peptide compound, wherein a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH comprises a hydrophilic N-acyl moiety, a dipolar moiety, a sulfonium moiety, a receptor-modifying moiety or a small polar moiety.
-
公开(公告)号:WO9640757A3
公开(公告)日:1997-02-20
申请号:PCT/US9609852
申请日:1996-06-07
Applicant: INDIANA UNIVERSITY FOUNDATION , ROESKE ROGER W
Inventor: ROESKE ROGER W
CPC classification number: C07K7/23 , A61K38/00 , Y10S930/13
Abstract: Novel LHRH antagonist peptides, pharmaceutical compositions thereof, and methods of use thereof, are disclosed. The LHRH antagonist comprise a peptide compound, wherein a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH comprises a hydrophilic N-acyl moiety, a dipolar moiety, a sulfonium moiety, a receptor-modifying moiety or a small polar moiety.
-
-
-
-